Cargando…

A novel mesenchymal stem cell-based regimen for acute myeloid leukemia differentiation therapy

Currently the main treatment of acute myeloid leukemia (AML) is chemotherapy combining hematopoietic stem cell transplantation. However, the unbearable side effect of chemotherapy and the high risk of life-threatening infections and disease relapse following hematopoietic stem cell transplantation r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Luchen, Yang, Nanfei, Chen, Bing, Bei, Yuncheng, Kang, Zisheng, Zhang, Can, Zhang, Nan, Xu, Peipei, Yang, Wei, Wei, Jia, Ke, Jiangqiong, Sun, Weijian, Li, Xiaokun, Shen, Pingping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372914/ https://www.ncbi.nlm.nih.gov/pubmed/37521858 http://dx.doi.org/10.1016/j.apsb.2023.05.007

Ejemplares similares

Establishment of a novel mesenchymal stem cell-based regimen for chronic myeloid leukemia differentiation therapy
por: Zuo, Shiman, et al.
Publicado: (2021)

PFKFB4 facilitates palbociclib resistance in oestrogen receptor‐positive breast cancer by enhancing stemness
por: Wang, Sijie, et al.
Publicado: (2022)

Blockage of PPARγ T166 phosphorylation enhances the inducibility of beige adipocytes and improves metabolic dysfunctions
por: Yang, Nanfei, et al.
Publicado: (2022)

Intervening pyruvate carboxylase stunts tumor growth by strengthening anti-tumor actions of tumor-associated macrophages
por: Shu, Yuxin, et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

CDK5 Inhibition Abrogates TNBC Stem‐Cell Property and Enhances Anti‐PD‐1 Therapy
por: Bei, Yuncheng, et al.
Publicado: (2020)

Clinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemia
por: LUO, SHENG, et al.
Publicado: (2013)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

The “7+3” regimen in acute myeloid leukemia
por: Rowe, Jacob M.
Publicado: (2022)

Regulation of Malignant Myeloid Leukemia by Mesenchymal Stem Cells
por: Tan, Zhenya, et al.
Publicado: (2022)

The impact of venetoclax based regimens in the preemptive of measurable residual disease in acute myeloid leukemia
por: Fang, Qiuyun, et al.
Publicado: (2022)

HAG regimen improves survival in adult patients with hypocellular acute myeloid leukemia
por: Hu, Xiaoxia, et al.
Publicado: (2015)

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
por: Maiti, Abhishek, et al.
Publicado: (2022)

S-nitrosylation of ERK inhibits ERK phosphorylation and induces apoptosis
por: Feng, Xiujing, et al.
Publicado: (2013)

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients with Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study
por: Liu, Xiaoyu, et al.
Publicado: (2021)

Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens
por: Chen, Peng, et al.
Publicado: (2018)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
por: Tong, Xiwen, et al.
Publicado: (2023)

Decitabine combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia
por: Zhao, Haitao, et al.
Publicado: (2020)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
por: Sciumè, Mariarita, et al.
Publicado: (2023)

Acute Myeloid Leukemia Cells Educate Mesenchymal Stromal Cells toward an Adipogenic Differentiation Propensity with Leukemia Promotion Capabilities
por: Zhang, Luwen, et al.
Publicado: (2022)

A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia
por: Wang, Jingbo, et al.
Publicado: (2018)

TMT-based comprehensive proteomic profiling identifies serum prognostic signatures of acute myeloid leukemia
por: Zhang, Wei, et al.
Publicado: (2023)

Clinical significance of miR-372 and miR-495 in acute myeloid leukemia
por: Zhang, Wei, et al.
Publicado: (2020)

Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
por: Zhu, Xiongpeng, et al.
Publicado: (2010)

Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia
por: Vey, Norbert
Publicado: (2020)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

SCAMP2/5 as diagnostic and prognostic markers for acute myeloid leukemia
por: Yue, Can, et al.
Publicado: (2021)

Increased number of mast cells in the bone marrow of chronic myeloid leukemia may herald the pending myeloid transformation—the mast cell is an indicator of myeloid transformation
por: Xu, Peipei, et al.
Publicado: (2019)

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia
por: Yin, Jia, et al.
Publicado: (2021)

PB1850: MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION COMBINED WITH CLAG REGIMEN IN REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA (NON-M3)
por: Wan, Kai, et al.
Publicado: (2023)

Primary Philadelphia chromosome positive acute myeloid leukemia: A case report
por: Shao, Xiaoyan, et al.
Publicado: (2018)

Alkaloid-based regimen is beneficial for acute myeloid leukemia resembling acute promyelocytic leukemia with NUP98/RARG fusion and RUNX1 mutation: A case report
por: Wei, Wei, et al.
Publicado: (2020)

Molecular mechanisms for stemness maintenance of acute myeloid leukemia stem cells
por: Wang, Jiazhen, et al.
Publicado: (2019)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism
por: Wang, Fenglin, et al.
Publicado: (2022)

A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China
por: Wang, Jianmin, et al.
Publicado: (2009)

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
por: Wei, Guoqing, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_uh4vuh5vjo2a20r3a84c64i0in